drugset
drugset / Trial / NCT01207492

Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

NCT01207492 ↗

Phase 2 Completed 17 enrolled Andrew J. Wagner, MD, PhD Brigham and Women's Hospital · collabMassachusetts General Hospital · collabNovartis · collab
NaSingle-groupOpen-labelTreatment

Summary

Nilotinib is a drug that is used to treat a form of a blood cancer called leukemia. Nilotinib works by blocking the action of a protein that might be important for the growth of pigmented villonodular synovitis (PVNS). In this research study the investigators are testing whether nilotinib can stop the growth of PVNS or improve the symptoms experienced from PVNS.

Timeline

Start
2010-09
Primary completion
2014-04
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 400 mg Oral

Indications

tenosynovial giant cell tumor, diffuse type